Ventria Bioscience Competitors and Similar CompaniesClear all
Ventria Bioscience's competitors and similar companies include Travere Therapeutics, Sosei Heptares, GBT (Global Blood Therapeutics) and Heron Therapeutics.
 Ventria Bioscience Ventria Bioscience develops life-saving medicines targeting inflammatory, infectious and gastrointestinal diseases. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Heron Therapeutics Heron Therapeutics (formerly A.P. Pharma) is a biotechnology company engaged in drug discovery and development. | ||
Founding Date | Founding Date 1993 | Founding Date 2011 | Founding Date 1990 | Founding Date 2012 | Founding Date 1983 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Junction City, US HQ Aurora, US | Locations San Diego, US HQ Dublin, IE | Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations San Diego, US HQ |
Employees | Employees 244% decrease | Employees 46293% increase | Employees 387 | Employees 352106% increase | Employees 20333% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) 697 m | Valuation ($) 4.4 b | Valuation ($) 268.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) ¥29.6b (FY, 2025) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) $154.9m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $10.3m (FY, 2025) | Cost of goods ¥7.3b (FY, 2025) | Cost of goods $3.3m (FY, 2021) | Cost of goods $41.3m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $480.4m (FY, 2025) | Gross profit ¥24b (FY, 2025) | Gross profit N/A | Gross profit $113.6m (FY, 2025) |
Net income | Net income N/A | Net income ($25.5m) (FY, 2025) | Net income (¥12.5b) (FY, 2025) | Net income ($303.1m) (FY, 2021) | Net income ($20.2m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 7.7m | Total funding raised $ 25m | Total funding raised $ 65m | Total funding raised $ 88.7m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Travere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View company
Sosei Heptares
HQ
Tokyo, JP
Employees
387
Sosei Heptares is a biopharmaceutical company that specializes in drug development.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyHeron Therapeutics
HQ
San Diego, US
Employees
203↓ 33% decrease
Heron Therapeutics (formerly A.P. Pharma) is a biotechnology company engaged in drug discovery and development.
View company